It's a hot market, so you can always expect some entity will be chasing a solution that will likely be added to the graveyard of failures over the past 20 years. FWIW, the IgaN indication is not the same as LN. As far as the LN indication, my research says the only trial that seemed promising was the NVS trial, and of course that one failed. LN is a very tricky disease. Auph is protected with patents through 2037 and now the standards, including KDIGO now (in its recent 2024 clinical practice guidelines for treating LN) recommend VOC/Lupkynis for treating LN class III and IV.
What's important to understand about KDIGO guidelines is that they not only recommend VOC/Lupkynis, but my understanding is that the guidelines emphasize that VOC/Lupkynis is the only option that received KDIGO's a high certainty of evidence rating ... that is KDIGO finds high certainty of evidence that the the therapy that adds VOC to the baseline therapy is superior over the baseline therapy alone. The other options, not so good ... read for yourself at page S32 of KDIGO's practice guidelines. It seems pretty clear that this is a big step toward VOC becoming the new SOC. WT [/img] https://sih-st-charts.stocktwits-cdn.com/production/original_559447358.png [/img]
News 
Market Data 
Discover 
